On Cancer

and/or

74 Blog posts found

In the Clinic

Getting the Most from Bladder Cancer Immunotherapy Drugs

Bladder cancer is more likely to respond to immunotherapy drugs if the tumors carry mutations in DNA repair genes.

Colored transmission electron micrograph (TEM) of a bladder cancer cell stained orange. The cell is large and has many nuclei (purple).

In the Clinic

Longest-Running CAR T Trial Shows Which Patients Benefit Most, Have Fewest Side Effects

For adults with chemotherapy-resistant leukemia, CAR T cell therapy can be a lifesaving treatment option. New results suggest how to make it safer.

Medical oncologist Jae Park

Q&A

Immunotherapy Offers New Strategy for Treating Sarcoma

Some of the first clinical trials testing immunotherapy for the treatment of sarcoma are now under way at MSK. Here’s a snapshot of where the research stands.

Enlarged microscopic image of blue-green immune cells surrounding one blue cancer cell.

Feature

4 Inspiring MSK Patients We Met This Year

Catch up with some of the patients we got to know in 2017.

Family of four posing on the boardwalk at the beach

In the News

Advances in Multiple Myeloma, Lymphoma, and Histiocytosis among Results Presented at 2017 ASH Meeting

The 2017 American Society of Hematology meeting featured news on promising advances in the treatment of blood cancers.

A crowd at the meeting of the American Society for Hematology

Q & A

Study Uncovers Genetic Reasons Why Some People Respond to Immunotherapy Better than Others

Immunotherapy drugs called checkpoint inhibitors have been a game changer for some people with cancer. But for most patients, these drugs have been disappointing. Researchers are trying to figure out why.

Model of a T cell receptor and an HLA-A white blood cell antigen bound to part of a virus

In the Clinic

What Is Metastatic Cancer? Answers to Six Common Questions

Learn about MSK’s approach to treating cancer that has spread from the original tumor to other parts of the body.

A color image of a liver with metastatic tumors

Finding

Why Do Some People Beat the Odds against Pancreatic Cancer?

Scientists think they now understand why some people with pancreatic cancer survive for many years. Hint: It involves the immune system.

An illustration of the human pancreas

In the Lab

Why Do Immune Checkpoint Inhibitors Work for Only Some People with Cancer?

Learn about why checkpoint inhibitors, a class of immunotherapy drugs, 
is paying off — but only for some patients.

MSK physician­scientist Luis Diaz

Announcement

FDA Approves CAR T Cell Therapy for Non-Hodgkin Lymphoma

This is the second regulatory approval of the cell-based immunotherapy for a blood cancer.

Medical oncologist Anas Younes